Neuronetics, Inc. Common Stock (STIM) Stock
Key stats
- Market cap
- $143.63M
- Price / Earnings ratio
- -4.7x
- EPS (TTM)
- -$0.44
- Volume
- Loading
- 52-week high
- $3.44
- 52-week low
- $0.80
Source: third-party data provider, as of October 16, 2026
Compare with STIM
Recent news

Neuronetics Q2 Earnings Call Highlights
Neuronetics Q2 Earnings Call Highlights
STIM

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
STIM

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
STIM

Why Is STIM Stock Rallying 16% After-Hours?
Why Is STIM Stock Rallying 16% After-Hours?
STIM
Technical indicators
- RSI 14
- 27.75
- MACD 12/26/9
- -0.21
- EMA 9 of MACD
- -0.16
- MACD histogram
- -0.04
- SMA 50
- $2.70
- Price below SMA 50
- EMA 50
- $2.41
- Price below EMA 50
- SMA 200
- $1.85
- Price above SMA 200
- EMA 200
- $2.06
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Neuronetics Q2 Earnings Call Highlights
Neuronetics Q2 Earnings Call Highlights
STIM

Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
STIM

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
STIM

Why Is STIM Stock Rallying 16% After-Hours?
Why Is STIM Stock Rallying 16% After-Hours?
STIM

3 Neurotech Stocks Bridging Mind and Machine
3 Neurotech Stocks Bridging Mind and Machine
STIM

5 Winning Medical Product Stocks That Still Have Room to Run
5 Winning Medical Product Stocks That Still Have Room to Run
STIM

New Strong Buy Stocks for November 16th
New Strong Buy Stocks for November 16th
STIM
About Neuronetics, Inc. Common Stock
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel L. Reuvers | CEO, President & Director | 1963 |
| Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A. | Executive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer | 1975 |
| Mr. Robert Greene | Senior Vice President of Sales | — |
| Mr. Cory S. Anderson | Executive Vice President & General Manager of Greenbrook | 1977 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 16, 2026
Technical indicators
- RSI 14
- 27.75
- MACD 12/26/9
- -0.21
- EMA 9 of MACD
- -0.16
- MACD histogram
- -0.04
- SMA 50
- $2.70
- Price below SMA 50
- EMA 50
- $2.41
- Price below EMA 50
- SMA 200
- $1.85
- Price above SMA 200
- EMA 200
- $2.06
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $5.00
- Average
- $5.50
- High
- $6.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.2 | -28.2 | +14.4 | |||||||||
| 2022 | -20.8 | -7.7 | -7.9 | -21.8 | +6.3 | +19.3 | +31.1 | -16.0 | -9.4 | +7.8 | +81.5 | +10.8 |
| 2023 | -10.9 | -7.9 | -47.2 | -12.9 | +18.7 | -22.4 | -11.3 | -16.3 | -17.2 | -12.2 | +58.3 | +42.9 |
| 2024 | +23.6 | -10.4 | +58.1 | -29.9 | -46.1 | -6.2 | +6.9 | -50.6 | -12.6 | +37.3 | -2.9 | +45.0 |
| 2025 | +108.1 | +32.8 | -13.6 | +15.9 | -12.3 | -8.4 | +26.5 | -24.7 | -13.1 | -2.6 | -46.2 | -2.8 |
| 2026 | +45.1 | -32.7 | +12.4 | +30.2 | -23.8 | -22.2 | +46.7 | +31.5 | -17.6 | -12.2 |



